Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHFree Report) in a report issued on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of Bellerophon Therapeutics stock opened at $0.05 on Friday. The firm has a market cap of $623,730.00, a PE ratio of -0.06 and a beta of 0.68. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $12.58. The stock has a fifty day moving average price of $0.05 and a 200-day moving average price of $0.19.

Bellerophon Therapeutics (NASDAQ:BLPHGet Free Report) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter.

Institutional Investors Weigh In On Bellerophon Therapeutics

Institutional investors have recently bought and sold shares of the stock. HRT Financial LP bought a new stake in Bellerophon Therapeutics in the fourth quarter valued at approximately $25,000. BlackRock Inc. increased its stake in shares of Bellerophon Therapeutics by 34.8% in the second quarter. BlackRock Inc. now owns 129,876 shares of the biotechnology company’s stock worth $90,000 after buying an additional 33,527 shares during the period. Dimensional Fund Advisors LP bought a new stake in Bellerophon Therapeutics during the 1st quarter valued at $107,000. Acadian Asset Management LLC purchased a new position in shares of Bellerophon Therapeutics in the second quarter valued at about $182,000. Finally, State Street Corp raised its stake in shares of Bellerophon Therapeutics by 41.3% during the first quarter. State Street Corp now owns 30,127 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 8,800 shares during the last quarter. 28.88% of the stock is currently owned by hedge funds and other institutional investors.

About Bellerophon Therapeutics

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Read More

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.